Citigroup
AVDL

Citigroup’s Avadel Pharmaceuticals AVDL Stock Holding History

Citigroup’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,579
Closed -$487K – 5946
2025
Q4 		$487K Sell
22,579
-2,591
-10% -$50.3K ﹤0.01% 3581
2025
Q3 		$384K Sell
25,170
-15,467
-38% -$201K ﹤0.01% 3703
2025
Q2 		$360K Sell
40,637
-33,135
-45% -$291K ﹤0.01% 3802
2025
Q1 		$578K Sell
73,772
-8,044
-10% -$67.4K ﹤0.01% 3600
2024
Q4 		$860K Buy
81,816
+9,991
+14% +$121K ﹤0.01% 3471
2024
Q3 		$942K Buy
71,825
+46,571
+184% +$709K ﹤0.01% 3307
2024
Q2 		$355K Buy
25,254
+20,591
+442% +$336K ﹤0.01% 3599
2024
Q1 		$78.8K Buy
4,663
+1,137
+32% +$16.9K ﹤0.01% 4402
2023
Q4 		$49.8K Buy
3,526
+896
+34% +$10.5K ﹤0.01% 4523
2023
Q3 		$27.1K Buy
2,630
+697
+36% +$9.34K ﹤0.01% 4305
2023
Q2 		$31.9K Buy
1,933
+567
+42% +$7.37K ﹤0.01% 4837
2023
Q1 		$12.5K Buy
1,366
+637
+87% +$5.24K ﹤0.01% 4659
2022
Q4 		$5.22K Buy
729
+70
+11% +$491 ﹤0.01% 5026
2022
Q3 		$3K Sell
659
-200
-23% -$1.1K ﹤0.01% 5359
2022
Q2 		$2K Sell
859
-368
-30% -$1.51K ﹤0.01% 5854
2022
Q1 		$8K Sell
1,227
-520
-30% -$3.58K ﹤0.01% 5627
2021
Q4 		$14K Sell
1,747
-23,015
-93% -$210K ﹤0.01% 5485
2021
Q3 		$243K Buy
24,762
+21,221
+599% +$167K ﹤0.01% 4032
2021
Q2 		$24K Buy
3,541
+2,427
+218% +$19.3K ﹤0.01% 5189
2021
Q1 		$10K Sell
1,114
-798
-42% -$6.45K ﹤0.01% 5624
2020
Q4 		$13K Buy
+1,912
New +$12K ﹤0.01% 6853
2019
Q3 		– Sell
-1,720
Closed -$5K – 7683
2019
Q2 		$5K Sell
1,720
-1,718
-50% -$2.95K ﹤0.01% 7465
2019
Q1 		$5K Hold
3,438
– – ﹤0.01% 7408
2018
Q4 		$9K Hold
3,438
– – ﹤0.01% 7184
2018
Q3 		$15K Hold
3,438
– – ﹤0.01% 7202
2018
Q2 		$21K Sell
3,438
-181
-5% -$1.27K ﹤0.01% 6890
2018
Q1 		$26K Sell
3,619
-1,116
-24% -$9.82K ﹤0.01% 6589
2017
Q4 		$39K Sell
4,735
-5,030
-52% -$47.2K ﹤0.01% 6336
2017
Q3 		$102K Sell
9,765
-1,325
-12% -$12.7K ﹤0.01% 5547
2017
Q2 		$122K Sell
11,090
-828
-7% -$8.31K ﹤0.01% 5185
2017
Q1 		$116K Hold
11,918
– – ﹤0.01% 5096
2016
Q4 		$124K Sell
11,918
-3,973
-25% -$43.7K ﹤0.01% 5639
2016
Q3 		$197K Buy
15,891
+1,708
+12% +$22.3K ﹤0.01% 4668
2016
Q2 		$153K Sell
14,183
-344
-2% -$3.67K ﹤0.01% 4729
2016
Q1 		$160K Buy
14,527
+5,029
+53% +$50K ﹤0.01% 5294
2015
Q4 		$116K Sell
9,498
-252
-3% -$3.93K ﹤0.01% 5259
2015
Q3 		$159K Buy
9,750
+21
+0.2% +$463 ﹤0.01% 4674
2015
Q2 		$206K Buy
9,729
+243
+3% +$4.36K ﹤0.01% 4416
2015
Q1 		$171K Buy
9,486
+1,566
+20% +$24.5K ﹤0.01% 4656
2014
Q4 		$136K Buy
+7,920
New +$113K ﹤0.01% 4992
2014
Q2 		– Sell
-2,046
Closed -$27K – 7101
2014
Q1 		$27K Buy
2,046
+2,009
+5,430% +$21.5K ﹤0.01% 5860
2013
Q4 		$0 Sell
37
-133
-78% -$939 ﹤0.01% 6971
2013
Q3 		$1K Sell
170
-63
-27% -$387 ﹤0.01% 6647
2013
Q2 		$1K Buy
+233
New +$1.2K ﹤0.01% 6604

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Citigroup's AVDL Position: Q1 2026 in Review

Citigroup sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 22,579 shares — an estimated $487K sold.

Citigroup first reported a position in AVDL in Q2 2013 and held it in 44 quarters. The position peaked at $942K in Q3 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Citigroup reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 22,579 Avadel Pharmaceuticals shares in Q1 2026, an estimated $487K.
  • Citigroup first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 44 quarters.
  • Citigroup's Avadel Pharmaceuticals position peaked at $942K in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.